Nerve side effects study for new bladder cancer treatment
Part of Brain & nervous system, Cancer clinical trials.
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced bladder cancer that has spread or cannot be removed by surgery
- You have not had any other treatment for your advanced bladder cancer
- You are able to receive the study drugs enfortumab vedotin and pembrolizumab
- You have not taken certain chemotherapy or immunotherapy in the last 12 months before surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This study looks at how well the combination of enfortumab vedotin and pembrolizumab (EV+P) works as the first treatment for people with advanced or metastatic bladder cancer or other rare urinary tract tumors. By reviewing medical records, researchers hope to learn more about the benefits of this therapy.
This study looks at how enfortumab vedotin, a cancer drug, affects the nerves. It aims to understand and track neuropathy (nerve damage) in people with urothelial carcinoma, so doctors can better manage side effects.
This study watches for nerve damage (peripheral neuropathy) in patients receiving two cancer drugs—enfortumab vedotin and pembrolizumab—for advanced bladder cancer. Researchers will test whether a supportive medication called Neuridase can help prevent or reduce nerve pain and numbness that sometimes occurs with this treatment.
This study looks at whether enfortumab vedotin (EV) affects the nervous system in people with advanced bladder cancer. It follows patients who are getting EV (alone or with immunotherapy) to see how their nerve function changes over time.
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
Hear when a new Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.